New approaches in the diagnosis and treatment of latent tuberculosis infection

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Ahmad, Suhail ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

CYTOKINE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; LATENT TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RESUSCITATION; REVIEW; TUBERCULOSIS; MOLECULAR DIAGNOSIS;

ANTITUBERCULAR AGENTS; HUMANS; LATENT TUBERCULOSIS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 78649615608     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-169     Document Type: Review

References (216)

1. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393:537-544. 10.1038/31159, 9634230.
2. Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, Pryor M, Duthoy S, Grondin S, Lacroix C, Monsempe C, Simon S, Harris B, Atkin R, Doggett J, Mayes R, Keating L, Wheeler PR, Parkhill J, Barrell BG, Cole ST, Gordon SV, Hewinson RG. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003, 100:7877-7882. 10.1073/pnas.1130426100, 164681, 12788972.
3. World Health Organization Global tuberculosis control: surveillance, planning and financing. WHO report 2009. WHO/HTM/TB/2009.411 2009, Geneva, Switzerland: WHO, World Health Organization.
4. World Health Organization Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009.426 2009, Geneva, Switzerland: WHO, World Health Organization.
5. World Health Organization Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3 2010, Geneva, Switzerland: WHO, World Health Organization.
6. Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006, 100:415-431. 10.1179/136485906X91477, 16899146.
7. Dooley K, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009, 9:737-746. 10.1016/S1473-3099(09)70282-8, 2945809, 19926034.
8. Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Resp Med 2009, 103:1777-1790.
9. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003, 362:887-899. 10.1016/S0140-6736(03)14333-4, 13678977.
10. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Otu JK, Corrah T, Adegbola RA, McAdam KP. Large scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004, 38:966-973. 10.1086/382362, 15034828.
11. Bellamy R. Genetic susceptibility to tuberculosis. Clin Chest Med 2005, 26:233-246. 10.1016/j.ccm.2005.02.006, 15837108.
12. Dye C. Global epidemiology of tuberculosis. Lancet 2006, 367:938-940. 10.1016/S0140-6736(06)68384-0, 16546542.
13. Mathema B, Kurepina N, Fallows D, Kreisworth BN. Lessons from molecular epidemiology and comparative genomics. Semin Resp Crit Care Med 2008, 29:467-480.
14. Mokaddas E, Ahmad S. Species spectrum of nontuberculous mycobacteria isolated from clinical specimens in Kuwait. Curr Microbiol 2008, 56:413-417. 10.1007/s00284-008-9102-3, 18231831.
15. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Phys 2005, 72:1761-1768.
16. Mokaddas E, Ahmad S, Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 2008, 12:319-325.
17. Bermudez LE, Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 1996, 64:1400-1406. 173932, 8606107.
18. Teitelbaum R, Schubert W, Gunther L, Kress Y, Macaluso F, Pollard JW, McMurray DN, Bloom BR. The M cell as a portal of entry to the lung for the bacterial pathogen Mycobacterium tuberculosis. Immunity 1999, 10:641-650. 10.1016/S1074-7613(00)80063-1, 10403639.
19. Bermudez LE, Sangari FJ, Kolonoski P, Petrofski M, Goodman J. The efficiency of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells. Infect Immun 2002, 70:140-146. 10.1128/IAI.70.1.140-146.2002, 127600, 11748175.
20. Kinhikar AG, Verma I, Chandra D, Singh KK, Weldingh K, Andersen P, Hsu T, Jacobs WR, Laal S. Potential role for ESAT6 in dissemination of Mycobacterium tuberculosis via human lung epithelial cells. Mol Microbiol 2010, 75:92-106. 10.1111/j.1365-2958.2009.06959.x, 2846543, 19906174.
21. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002, 70:4501-4509. 10.1128/IAI.70.8.4501-4509.2002, 128141, 12117962.
22. Davis JM, Ramakrishnan L. The role of the granuloma in expansion of early tuberculous infection. Cell 2009, 136:37-49. 10.1016/j.cell.2008.11.014, 19135887.
23. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
24. Jo E-K. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs. Curr Opin Infect Dis 2008, 21:279-286. 10.1097/QCO.0b013e3282f88b5d, 18448973.
25. Dorhoi A, Kaufmann SH. Fine-tuning of T cell responses during infection. Curr Opin Immunol 2009, 21:367-377. 10.1016/j.coi.2009.07.004, 19646852.
26. Harding CV, Henry Boom W. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for toll-like receptors. Nat Rev Microbiol 2010, 8:296-307. 10.1038/nrmicro2321, 20234378.
27. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, Kinoshita T, Akira S, Yoshikai Y, Yamasaki S. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 2009, 206:2879-2888. 10.1084/jem.20091750, 2806462, 20008526.
28. Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, Golenbock DT, Boom WH, Harding CV. Toll-like receptor 2-dependant inhibition of macrophage class II MHC expression and antigen processing by 19 kD lipoprotein of Mycobacterium tuberculosis. J Immunol 2001, 167:910-918.
29. Yang CS, Lee JS, Song CH, Hur GM, Lee SJ, Tanaka S, Akira S, Paik TH, Jo EK. Protein kinase C zeta plays an essential role for Mycobacterium tuberculosis-induced extracellular signal-regulated kinase 1/2 activation in monocytes/macrophages via Toll-like receptor 2. Cell Microbiol 2007, 9:382-396. 10.1111/j.1462-5822.2006.00797.x, 16925784.
30. Jo EK, Yang CS, Choi CH, Harding CV. Intracellular signaling cascades regulating innate immune responses to mycobacteria: branching out from Toll-like receptors. Cell Microbiol 2007, 9:1087-1098. 10.1111/j.1462-5822.2007.00914.x, 17359235.
31. Jung SB, Yang CS, Lee JS, Shin AR, Jung SS, Son JW, Harding CV, Kim HJ, Park JK, Paik TH, Song CH, Jo EK. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun 2006, 74:2686-2696. 10.1128/IAI.74.5.2686-2696.2006, 1459749, 16622205.
32. Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH. Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR2 ligand that inhibits human macrophage class II antigen processing. J Immunol 2004, 173:2660-2668.
33. Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J Immunol 2006, 177:422-429.
34. Chitale S, Ehrt S, Kawamura I, Fujimura T, Shimono N, Anand N, Lu S, Cohen-Gould L, Riley LW. Recombinant Mycobacterium tuberculosis protein associated with mammalian cell entry. Cell Microbiol 2001, 3:247-254. 10.1046/j.1462-5822.2001.00110.x, 11298648.
35. Ahmad S, El-Shazly S, Mustafa AS, Al-Attiyah R. The six mammalian cell entry proteins (Mce3A-F) encoded by the mce3 operon are expressed during in vitro growth of Mycobacterium tuberculosis. Scand J Immunol 2005, 62:16-24. 10.1111/j.1365-3083.2005.01639.x, 16091122.
36. El-Shazly S, Ahmad S, Mustafa AS, Al-Attiyah R, Krajci D. The internalization of latex beads coated with mammalian cell entry (Mce) proteins encoded by mce3 operon of Mycobacterium tuberculosis by HeLa cells. J Med Microbiol 2007, 56:1145-1151. 10.1099/jmm.0.47095-0, 17761475.
37. Dennehy KM, Willment JA, Williams DL, Brown GD. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur J Immunol 2009, 39:1379-1386. 10.1002/eji.200838543, 2720084,2720084, 19291703.
38. Sani M, Houben EN, Geurtsen J, Pierson J, de Punder K, van Zon M, Wever B, Piersma SR, Jiménez CR, Daffé M, Appelmelk BJ, Bitter W, van der Wel N, Peters PJ. Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins. PLoS Pathog 2010, 6:e1000794. 10.1371/journal.ppat.1000794, 2832766, 20221442.
39. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TLR signalling. Nature 2003, 424:743-748. 10.1038/nature01889, 12872135.
40. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643. 10.1126/science.1087262, 12855817.
41. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007, 27:135-144. 10.1016/j.immuni.2007.05.022, 2680670, 17658277.
42. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003, 3:578-590. 10.1016/S1473-3099(03)00741-2, 12954564.
43. Chan J, Flynn J. The immunological aspects of latency in tuberculosis. Clin Immunol 2004, 110:2-12. 10.1016/S1521-6616(03)00210-9, 14986673.
44. Kusner DJ. Mechanisms of mycobacterial persistence in tuberculosis. Clin Immunol 2005, 114:239-247. 10.1016/j.clim.2004.07.016, 15721834.
45. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422. 10.1146/annurev.immunol.021908.132703, 19302046.
46. Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, Flynn JL. Depletion of CD4 T-cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon-γ and nitric oxide synthase. J Exp Med 2000, 192:347-358. 10.1084/jem.192.3.347, 2193220, 10934223.
47. Beetz S, Wesch D, Marischen L, Welte S, Oberg HH, Kabelitz D. Innate immune functions of human γδ T cells. Immunobiology 2008, 213:173-182. 10.1016/j.imbio.2007.10.006, 18406365.
48. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobactrium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992, 175:1111-1112. 10.1084/jem.175.4.1111, 2119182, 1552282.
49. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, Chan J. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun 2001, 69:7711-7717. 10.1128/IAI.69.12.7711-7717.2001, 98866, 11705952.
50. Rhode K, Yates RM, Purdy GE, Russell DG. Mycobactrium tuberculosis and the environment within the phagosome. Immunol Rev 2007, 219:37-54. 10.1111/j.1600-065X.2007.00547.x, 17850480.
51. Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 2008, 3:399-407. 10.1016/j.chom.2008.05.006, 18541216.
52. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263:678-681. 10.1126/science.8303277, 8303277.
53. Yates RM, Hermetter A, Russell DG. The kinetics of phagosome maturation as a function of phagosome/lysosome fusion and acquisition of hydrolytic activity. Traffic 2005, 6:413-420. 10.1111/j.1600-0854.2005.00284.x, 15813751.
54. Yadav M, Clark L, Schorey JS. Macrophage's proinflammatory response to a mycobacterial infection is dependant on sphingosine kinase-mediated activation of phosphatidylinositol phospholipase C, protein kinase C, ERK1/2, and phosphatidylinositol 3-kinase. J Immunol 2006, 176:5494-5503.
55. Alonso S, Pethe K, Russell DG, Purdy GE. Lysosomal killing of Mycobacterium tuberculosis mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc Natl Acad Sci USA 2007, 104:6031-6036. 10.1073/pnas.0700036104, 1851611, 17389386.
56. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-1 and CD1 in tuberculosis. Nat Med 2003, 9:1039-1046. 10.1038/nm906, 12872166.
57. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, Sandhoff K, Brinkmann V, Kaufmann SHE, Schaible UE. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006, 24:105-117. 10.1016/j.immuni.2005.12.001, 16413927.
58. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorina S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003, 425:397-402. 10.1038/nature01911, 14508489.
59. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D, Desjardins M. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 425:402-406. 10.1038/nature01912, 14508490.
60. Kang SJ, Cresswell P. Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat Immunol 2004, 5:175-181. 10.1038/ni1034, 14716312.
61. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol 2007, 7:929-941. 10.1038/nri2191, 18037897.
62. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996, 64:16-22. 173721, 8557334.
63. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998, 144:3195-3205. 10.1099/00221287-144-11-3195, 9846755.
64. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520-1523. 10.1126/science.284.5419.1520, 10348738.
65. Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 1999, 32:643-655. 10.1046/j.1365-2958.1999.01383.x, 10320585.
66. Guinn KM, Hickey MJ, Mathur SK, Zakel KL, Grotzke JE, Lewinsohn DM, Smith S, Sherman DR. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004, 51:359-370. 10.1046/j.1365-2958.2003.03844.x, 1458497, 14756778.
67. Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R. ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol 2004, 12:500-508. 10.1016/j.tim.2004.09.007, 15488391.
68. Gao LY, Guo S, McLaughlin B, Morisaki H, Engel JN, Brown EJ. A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion. Mol Microbiol 2004, 53:1677-1693. 10.1111/j.1365-2958.2004.04261.x, 15341647.
69. de jonge MI, Pehau-Arnaudet G, Fretz MM, Romain F, Bottai D, Brodin P, Honoré N, Marchal G, Jiskoot W, England P, Cole ST, Brosch R. ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol 2007, 189:6028-6034. 10.1128/JB.00469-07, 1952024, 17557817.
70. Derrick SC, Morris SL. The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cell Microbiol 2007, 9:1547-1555. 10.1111/j.1462-5822.2007.00892.x, 17298391.
71. Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect Immun 1996, 64:683-690. 173823, 8641767.
72. Bermudez LE, Danelishvili L, Early J. Mycobacteria and macrophage apoptosis: complex struggle for survival. Microbe 2006, 1:372-375.
73. Bodnar KA, Serbina NV, Flynn JL. Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect Immun 2001, 69:800-809. 10.1128/IAI.69.2.800-809.2001, 97955, 11159971.
74. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001, 69:1722-1728. 10.1128/IAI.69.3.1722-1728.2001, 98078, 11179349.
75. Russell DG. Who puts the tubercle in tuberculosis?. Nat Rev Microbiol 2007, 5:39-47. 10.1038/nrmicro1538, 17160001.
76. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, Ernst JD. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008, 205:105-115. 10.1084/jem.20071367, 2234384, 18158321.
77. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010, 327:466-469. 10.1126/science.1179663, 20007864.
78. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009, 17:193-198.
79. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, Chiosea I, Capuano SV, Fuhrman C, Klein E, Flynn JL. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009, 77:4631-4642. 10.1128/IAI.00592-09, 2747916, 19620341.
80. Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
81. Via LE, Lin PL, Ray SM, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE. Tuberculous granulomas are hypoxic in guinea pigs, rabbits and nonhuman primates. Infect Immun 2008, 76:2333-2340. 10.1128/IAI.01515-07, 2423064, 18347040.
82. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005, 5:446-458. 10.1038/nri1630, 15928677.
83. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131:1124-1135. 10.1016/j.cell.2007.10.034, 18083102.
84. Shiloh MU, Manzanillo P, Cox JS. Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe 2008, 3:323-330. 10.1016/j.chom.2008.03.007, 2873178, 18474359.
85. Kumar A, Deshane JS, Crossman DK, Bolisetty S, Yan BS, Kramnik I, Agarwal A, Steyn AJ. Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem 2008, 283:18032-18039. 10.1074/jbc.M802274200, 2440631, 18400743.
86. Rustad TR, Sherrid AM, Minch KJ, Sherman DR. Hypoxia: a window into Mycobacterium tuberculosis latency. Cell Microbiol 2009, 11:1151-1159. 10.1111/j.1462-5822.2009.01325.x, 19388905.
87. Shiloh MU, DiGiuseppe Champion PA. To catch a killer. What can mycobacterial models teach us about Mycobacterium tuberculosis pathogenesis. Curr Opin Microbiol 2010, 13:86-92. 10.1016/j.mib.2009.11.006, 2876343, 20036184.
88. Nigou J, Zella-Rieser C, Gilleron M, Thurnher M, Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J Immunol 2001, 166:7477-7485.
89. Tobian AAR, Potter NS, Ramachandra L, Pai RK, Convery M, Boom WH, Harding CV. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide. J Immunol 2003, 171:1413-1422.
90. Pai RK, Pennini ME, Tobian AA, Canaday DH, Boom WH, Harding CV. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis ant its 19-kilodalton lipoprotein inhibits gamma-interferon-induced regulation of selected genes in macrophages. Infect Immun 2004, 72:6603-6614. 10.1128/IAI.72.11.6603-6614.2004, 523004, 15501793.
91. Briken V, Porcelli S, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol 2004, 53:391-403. 10.1111/j.1365-2958.2004.04183.x, 15228522.
92. Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, DesJardin LE, Schlesinger LS. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005, 202:987-999. 10.1084/jem.20051239, 2213176, 16203868.
93. Axelrod S, Oschkinat H, Enders J, Schlegel B, Brinkmann V, Kaufmann SHE, Haas A, Schaible UE. Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. Cell Microbiol 2008, 10:1530-1545. 10.1111/j.1462-5822.2008.01147.x, 18363878.
94. Kan-Sutton C, Jagannath C, Hunter RL. Trehalose 6,6'-dimycolate on the surface of Mycobacterium tuberculosis modulates surface marker expression for antigen presentation and costimulation in murine macrophages. Microb Infect 2009, 11:40-48.
95. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, Tryggvason K, Gordon S, Russell DG. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog 2009, 5:e1000474. 10.1371/journal.ppat.1000474, 2688075, 19521507.
96. Baena A, Porcelli SA. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 2009, 74:189-204. 10.1111/j.1399-0039.2009.01301.x, 2753606, 19563525.
97. Chang ST, Linderman JJ, Kirschner DE. Multiple mechanisms allow Mycobacterium tuberculosis to continuously inhibit MHC class II-mediated antigen presentation by macrophages. Proc Natl Acad Sci USA 2005, 102:4530-4535. 10.1073/pnas.0500362102, 555518, 15767567.
98. Ohno H, Zhu G, Mohan VP, Chu D, Kohno S, Jacobs WR, Chan J. The effects of reactive nitrogen intermediates on gene expression in Mycobacterium tuberculosis. Cell Microbiol 2003, 5:637-648. 10.1046/j.1462-5822.2003.00307.x, 12925133.
99. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. Inhibition of respiration by nitric oxide induces a Mycobactrium tuberculosis dormancy program. J Exp Med 2003, 198:705-713. 10.1084/jem.20030205, 2194188, 12953092.
100. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002, 43:717-731. 10.1046/j.1365-2958.2002.02779.x, 11929527.
101. Lin MY, Ottenhoff TH. Not to wake a sleeping giant: New insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem 2008, 389:497-511. 10.1515/BC.2008.057, 18953716.
102. Ghosh J, Larsson P, Singh B, Pettersson BM, Islam NM, Sarkar SN, Dasgupta S, Krisebom LA. Sporulation in mycobacteria. Proc Natl Acad Sci USA 2009, 106:10781-10786. 10.1073/pnas.0904104106, 2705590, 19541637.
103. Purdy GE, Niederweis M, Russell DG. Decreased outer membrane permeability protects mycobacteria from killing by ubiquitin-derived peptides. Mol Microbiol 2009, 73:844-857. 10.1111/j.1365-2958.2009.06801.x, 2747030, 19682257.
104. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282:677-686. 10.1001/jama.282.7.677, 10517722.
105. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis-the perfect storm. J Infect Dis 2007, 196(Suppl 1):S86-S107. 10.1086/518665, 17624830.
106. Hett EC, Chao MC, Steyn AJ, Fortune SM, Deng LL, Rubin EJ. A partner for the resuscitation-promoting factors of Mycobacterium tuberculosis. Mol Microbiol 2007, 66:658-668. 10.1111/j.1365-2958.2007.05945.x, 17919286.
107. Kana BD, Gordhan BG, Downing KJ, Sung N, Vostroktunova G, Machowski EE, Tsenova L, Young M, Keprelyants A, Kaplan G, Mizrahi V. The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol 2008, 67:672-684. 10.1111/j.1365-2958.2007.06078.x, 2229633, 18186793.
108. Russell-Goldman E, Xu J, Wang X, Chan J, Tufariello JM. A Mycobacterium tuberculosis Rpf double-knockout strain exhibits profound defects in reactivation from chronic tuberculosis and innate immunity phenotypes. Infect Immun 2008, 76:4269-4281. 10.1128/IAI.01735-07, 2519441, 18591237.
109. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on risk of being infected with tubercle bacilli. Adv Tuberc Res 1976, 19:1-63.
110. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 2002, 185:401-404. 10.1086/338342, 11807725.
111. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol 2006, 208:261-269. 10.1002/path.1906, 16362982.
112. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766. 10.1016/j.cell.2004.11.038, 15607973.
113. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974, 99:131-138.
114. Ahmad S, Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents 2005, 26:205-212. 10.1016/j.ijantimicag.2005.06.009, 16099622.
115. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 2009, 37:80-86. 10.1007/s15010-008-8087-y, 19308318.
116. Cardona PJ. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets 2007, 6:27-39. 10.2174/187152807780077282, 17352686.
117. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129:1287-1298. 10.1016/j.cell.2007.05.059, 17604718.
118. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile JF, Marchou B, Cardona PJ, de Chastellier C, Altare F. Foamy macrophages from tuberculous patients granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 2008, 4:e1000204. 10.1371/journal.ppat.1000204, 2575403, 19002241.
119. Caceres N, Tapia G, Ojanguren I, Altare F, Gil O, Pinto S, Vilaplana C, Cardona PJ. Evolution of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models. Tuberculosis 2009, 89:175-182. 10.1016/j.tube.2008.11.001, 19110471.
120. Garton NJ, Christensen H, Minnikin DE, Minnikin DE, Adegbola RA, Barer MR. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002, 148:2951-2958.
121. Cardona PJ, Llatjos R, Gordillo S, Díaz J, Ojanguren I, Ariza A, Ausina V. Evolution of granulomas in mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 2000, 52:156-163. 10.1046/j.1365-3083.2000.00763.x, 10931383.
122. Wiker HG, Mustafa T, Bjune GA, Harboe M. Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect Dis 2010, 10:37. 10.1186/1471-2334-10-37, 2843612, 20178619.
123. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM, Lange C, . for the TBNET LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Resp J 2009, 33:956-973. for the TBNET.
124. Lalvani A, Pareek M. A 100 year update on diagnosis of tuberculosis infection. Br Med Bull 2010, 93:69-84. 10.1093/bmb/ldp039, 19926636.
125. Pai M, O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 2008, 29:560-568. 10.1055/s-0028-1085707, 18810689.
126. Pai M, Zwerling A, Menzies D. T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184. 2951987, 18593687.
127. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis 1993, 17:976-975.
128. American Thoracic Society, Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S247. American Thoracic Society, Centers for Disease Control and Prevention.
129. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria. Int J Tuberc Lung Dis 2006, 10:1192-1204.
130. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacillus Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002, 57:804-809. 10.1136/thorax.57.9.804, 1746436, 12200526.
131. van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 2000, 7:155-160. 95842, 10702486.
132. Arend SM, Franken WP, Aggerbeck H, Prins C, van Dissel JT, Thierry-Carstensen B, Tingskov PN, Weldingh K, Andersen P. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis 2008, 88:249-261. 10.1016/j.tube.2007.11.004, 18155963.
133. Wu X, Zhang L, Zhang J, Zhang C, Zhu L, Shi Y. Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection. Clin Exp Immunol 2008, 152:81-87. 10.1111/j.1365-2249.2008.03605.x, 2384056, 18321349.
134. Weldingh K, Andersen P. ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. PLoS One 2008, 3:e1978. 10.1371/journal.pone.0001978, 2292253, 18431468.
135. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356:1099-1104. 10.1016/S0140-6736(00)02742-2, 11009160.
136. Arend SM, Engelhard ACF, Groot G, De Boer K, Andersen P, Ottenhoff THM, van Dissel JT. Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. Clin Diagn Lab Immunol 2001, 8:1089-1096. 96231, 11687445.
137. Brock I, Munk ME, Kok-Jensen A, Andersen P. Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 2001, 5:462-467.
138. Lalvani A. Spotting latent infection: the path to tuberculosis control. Thorax 2003, 58:916-918. 10.1136/thorax.58.11.916, 1746498, 14586040.
139. Pai M, Riley LW, Colford JM. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004, 4:761-776. 10.1016/S1473-3099(04)01206-X, 15567126.
140. Whalen CC. Diagnosis of latent tuberculosis infection: measure for measure. JAMA 2005, 293:2785-2787. 10.1001/jama.293.22.2785, 15941809.
141. Mazurek GH, Villarino ME, . CDC Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. M M W R Recomm Rep 2003, 52(RR-2):15-18. CDC.
142. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007, 131:1898-1906. 10.1378/chest.06-2471, 17565023.
143. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007, 146:340-354.
144. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010, 16:271-284.
145. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54(RR-15):49-55.
146. National Collaborating Centre for Chronic Conditions Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2006, London, UK: Royal College of Physicians, National Collaborating Centre for Chronic Conditions.
147. Jafari C, Thijsen S, Sotgiu G, Goletti D, Benítez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, Richeldi L, Ernst M, Lange C, . Tuberculosis Network European Trialsgroup Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med 2009, 180:666-673. 10.1164/rccm.200904-0557OC, 2753791, 19590020, Tuberculosis Network European Trialsgroup.
148. Strassburg A, Jafari C, Ernst M, Lotz W, Lange C. Rapid diagnosis of pulmonary TB by BAL enzyme-linked immunospot assay in an immunocompromised host. Eur Respir J 2008, 31:1132-1135. 10.1183/09031936.00083707, 18448508.
149. Kim SH, Chu K, Choi SJ, Song KH, Kim HB, Kim NJ, Park SH, Yoon BW, Oh MD, Choe KW. Diagnosis of central nervous system tuberculosis by T-cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Vaccine Immunol 2008, 15:1356-1362. 10.1128/CVI.00040-08, 2546678, 18632925.
150. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009, 4:e8517. 10.1371/journal.pone.0008517, 2795193, 20041113.
151. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2003, 347:1860-1866.
152. Abal AT, Ahmad S, Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist 2002, 8:99-105. 10.1089/107662902760190644, 12118524.
153. Ahmad S, Mokaddas E, Fares E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis 2002, 44:245-252. 10.1016/S0732-8893(02)00457-1, 12493171.
154. Ahmad S, Fares E, Araj GF, Chugh TD, Mustafa AS. Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut. Int J Tuberc Lung Dis 2002, 6:920-926.
155. Ahmad S, Mokaddas E. Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. Int J Antimicrob Agents 2004, 23:473-479. 10.1016/j.ijantimicag.2003.10.004, 15120726.
156. Ahmad S, Jaber A-A, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007, 87:123-129. 10.1016/j.tube.2006.05.004, 17289435.
157. Al-Zarouni M, Dash N, Al Ali M, Al-Shehhi F, Panigrahi D. Tuberculosis and MDR-TB in the northern emirates of United Arab Emirates: a 5-year study. Southeast Asian J Trop Med Public Health 2010, 41:163-168.
158. Fuhrmann S, Streitz M, Kern F. How flow cytometry is changing the study of TB immunology and clinical diagnosis. Cytometry A 2008, 73:1100-1106.
159. Ahmad S, Amoudy HA, Thole JE, Young DB, Mustafa AS. Identification of a novel protein antigen encoded by a Mycobacterium tuberculosis-specific RD1 region gene. Scand J Immunol 1999, 49:515-522. 10.1046/j.1365-3083.1999.00531.x, 10320645.
160. Ahmad S, El-Shazly S, Mustafa AS, Al-Attiyah R. Mammalian cell-entry proteins encoded by the mce3 operon of Mycobacterium tuberculosis are expressed during natural infection in humans. Scand J Immunol 2004, 60:382-391. 10.1111/j.0300-9475.2004.01490.x, 15379863.
161. Singh KK, Dong Y, Patibandla SA, McMurray DN, Arora VK, Laal S. Immunogenicity of the Mycobacterium tuberculosis PPE55 (Rv3347c) protein during incipient and clinical tuberculosis. Infect Immun 2005, 73:5004-5014. 10.1128/IAI.73.8.5004-5014.2005, 1201194, 16041015.
162. El-Shazly S, Mustafa AS, Ahmad S, Al-Attiyah R. Utility of three mammalian cell-entry proteins of Mycobacterium tuberculosis in the serodiagnosis of tuberculosis. Int J Tuberc Lung Dis 2007, 11:676-682.
163. Centers for Disease Control and Prevention Guidelines for the investigation of contacts with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005, 54(RR-15):1-47. Centers for Disease Control and Prevention.
164. Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005, 293:2776-2784. 10.1001/jama.293.22.2776, 15941808.
165. International Union Against Tuberculosis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Org 1982, 60:555-564. 2536088, 6754120, International Union Against Tuberculosis.
166. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 1999, 3:847-850.
167. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003, 168:443-447. 10.1164/rccm.200303-390OC, 12746255.
168. Horsburg CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004, 350:2060-2067. 10.1056/NEJMsa031667, 15141044.
169. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004, 170:445-449. 10.1164/rccm.200404-478OC, 15172892.
170. Tulsky JP, Pilote L, Hahn JA, Zolopa AJ, Burke M, Chesney M, Moss AR. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000, 160:697-702. 10.1001/archinte.160.5.697, 10724056.
171. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1,000 patients. JAMA 1979, 241:1239-1241. 10.1001/jama.241.12.1239, 762788.
172. Dickinson DS, Bailey WC, Hirschowitz BJ, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol 1981, 3:271-279. 10.1097/00004836-198109000-00012, 7288121.
173. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281:1014-1018. 10.1001/jama.281.11.1014, 10086436.
174. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980, 61:191-196. 10.1016/0041-3879(80)90038-0, 6269259.
175. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996, 154:1473-1477.
176. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997, 155:1735-1738.
177. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004, 170:832-835. 10.1164/rccm.200405-584PP, 15297274.
178. Lardizabal A, Passannate M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006, 130:1712-1717. 10.1378/chest.130.6.1712, 17166986.
179. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE. Improved adherence and less toxicity with rifampin vs isoniazid for the treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006, 166:1863-1870. 10.1001/archinte.166.17.1863, 17000943.
180. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008, 149:689-697.
181. Nolan CM, Williams DL, Donald Cave M, Eisenach KD, El-Hajj H, Hooton TM, Thompson RL, Goldberg SV. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995, 152:1067-1071.
182. Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999, 159:468-472.
183. Perlman DC, El Sadr WM, Nelson ET, Matts JP, Telzak EE, Salomon N, Chirgwin K, Hafner R. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997, 25:242-246. 10.1086/514546, 9332519.
184. Crampin AC, Floyd S, Mwanungulu F, Black G, Ndhlovu R, Mwaiyeghele E, Glynn JR, Warndorff DK, Fine PE. Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. Int J Tuberc Lung Dis 2001, 5:994-999.
185. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998, 113:1178-1183. 10.1378/chest.113.5.1178, 9596291.
186. Mokaddas E, Ahmad S, Abal AT, Al-Shami AS. Molecular fingerprinting reveals familial transmission of rifampin-resistant tuberculosis in Kuwait. Ann Saudi Med 2005, 25:150-153.
187. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998, 351:678-792. 10.1016/S0140-6736(97)06532-X, 9500362.
188. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ, . Terry Bairn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000, 283:1445-1450. 10.1001/jama.283.11.1445, 10732934, Terry Bairn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
189. Centers for Disease Control and Prevention Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:735-739. Centers for Disease Control and Prevention.
190. Gao X-F, Wang L, Liu G-L, Wen J, Sun X, Xie Y, Li Y-P. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta analysis. Int J Tuberc Lung Dis 2006, 10:1080-1090.
191. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ, . Terry Beirn Community Programs for Clinical Research on AIDS; Adult AIDS Clinical Trials Group, Centers for Disease Control and Prevention Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?. Clin Infect Dis 2004, 39:561-565. 10.1086/422724, 15356822, Terry Beirn Community Programs for Clinical Research on AIDS; Adult AIDS Clinical Trials Group, Centers for Disease Control and Prevention.
192. Tortajada C, Martinez-Lacasa J, Sanchez F, Jimenez-Fuentes A, De Souza ML, Garcia JF, Martinez JA, Cayla JA. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected with the human immunodeficiency virus?. Int J Tuberc Lung Dis 2005, 9:276-281.
193. Ena J, Valls V. Short-course therapy with rifampin and isoniazid for latent tuberculosis infection: a meta analysis. Clin Infect Dis 2005, 40:670-676. 10.1086/427802, 15714411.
194. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, Gourgiotis D, Tsolia MN. The effectiveness of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2006, 45:715-722.
195. Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007, 30:728-735. 10.1183/09031936.00034007, 17626113.
196. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S, . Tuberculosis Trials Consortium Pharmacokinetics of rifapentine at 600, 900 and 1,200 mg during once weekly tuberculosis therapy. Am J Respir Crit Care Med 2004, 169:1191-1197. 10.1164/rccm.200311-1612OC, 14962821, Tuberculosis Trials Consortium.
197. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006, 173:922-926. 10.1164/rccm.200512-1953OC, 2662911, 16474028.
198. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006, 10:19-23.
199. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997, 24:1264-1265.
200. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004, 169:421-426. 10.1164/rccm.200310-1380OC, 14578218.
201. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, . Gatifloxacin for TB (OFLOTUB) study team A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138. Gatifloxacin for TB (OFLOTUB) study team.
202. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005, 172:1452-1456. 10.1164/rccm.200507-1047OC, 1853317,1853317, 16151038.
203. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008, 52:1522-1524. 10.1128/AAC.00074-08, 2292539, 18285479.
204. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLos Med 2006, 3:e466. 10.1371/journal.pmed.0030466, 1664607, 17132069.
205. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227. 10.1126/science.1106753, 15591164.
206. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006, 50:3543-3547. 10.1128/AAC.00766-06, 1635167, 16954317.
207. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005, 56:968-974. 10.1093/jac/dki319, 16172107.
208. Nikonenko BV, Protopopova MN, Samala R, Einck L, Nacy CA. Drug therapy of experimental TB: improved outcome by combining SQ109, a new diamine antibiotic with existing TB drugs. Antimicrob Agents Chemother 2007, 51:1563-1565. 10.1128/AAC.01326-06, 1855523, 17242141.
209. Kaufmann SHE. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33:567-577. 10.1016/j.immuni.2010.09.015, 21029966.
210. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010, 375:2110-2119. 10.1016/S0140-6736(10)60393-5, 20488515.
211. Parida SK, Kaufmann SHE. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 2010, 22:374-384. 10.1016/j.coi.2010.04.006, 20471231.
212. Grode L, Seiler P, Baumann S, Hess J, Brinkman V, Nasse Eddin A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerrin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479. 10.1172/JCI24617, 1187936, 16110326.
213. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 2008, 76:5200-5214. 10.1128/IAI.00434-08, 2573348, 18725418.
214. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Adler N, Van Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H. Safety and immunogenicity of a new tuberculosis vaccine MVA85A in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009, 179:724-733. 10.1164/rccm.200809-1486OC, 2858810, 19151191.
215. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32. 10.1016/j.it.2008.09.006, 19059004.
216. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, Kromann I, Doherty TM, Andersen P. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 2010, 28:3571-3581. 10.1016/j.vaccine.2010.02.094, 20226890.